FDA approves Icotyde for moderate-to-severe plaque psoriasis

Johnson & Johnson said the FDA has approved Icotyde (icotrokinra) for moderate-to-severe plaque psoriasis in adults and in pediatric patients age 12 and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. The March 18, 2026 approval gives the market its first approved targeted oral peptide that blocks the IL-23 receptor, with once-daily dosing on an empty stomach. The approval follows Johnson & Johnson’s phase 3 ICONIC program, including placebo-controlled and active-comparator trials, and adds a new oral option in a treatment landscape still dominated by injectables and other systemic agents. (investor.jnj.com)

Why it matters: For veterinary professionals tracking the broader regulatory and immunology landscape, this approval is another sign that selective cytokine-pathway modulation is continuing to move toward more convenient oral formats. Icotyde’s label includes infection, tuberculosis, and immunization considerations, and the most common adverse reactions reported through 16 weeks were headache, nausea, cough, fungal infection, and fatigue. While the product is for human medicine, approvals like this can shape expectations around oral immune-mediated disease management, translational research, and pet parent interest in newer targeted therapies across species. (fda.report)

What to watch: Johnson & Johnson is already highlighting 52-week phase 3 data and ongoing head-to-head development work, so the next signals will likely be uptake, payer positioning, and whether icotrokinra expands into additional inflammatory indications. (investor.jnj.com)